Q2 2025 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2025-08-14 · accession 0001831942-25-000008
$1.42B
Reported value
33
Positions
2025-06-30
Period end
The Brief · Commodore Capital LP · Q2 2025
AI · grounded in 13F
Commodore Capital LP established a new position in MERUS N V valued at $185.4M. The fund also initiated new stakes in NUVL for $104.9M and XENE for $94.7M. Additional new positions include ELVN at $94.1M and AGIO at $77.3M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $185.4M | 13.1% | 3,525,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $104.9M | 7.41% | 1,375,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $94.7M | 6.68% | 3,025,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $94.1M | 6.64% | 4,692,809 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $77.3M | 5.46% | 2,325,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $70.2M | 4.96% | 3,450,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $70.1M | 4.95% | 2,450,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $68.2M | 4.81% | 4,875,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $59.4M | 4.19% | 1,075,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $57.2M | 4.04% | 1,175,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $51.4M | 3.63% | 1,450,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $51.1M | 3.61% | 610,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $46.2M | 3.26% | 13,350,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $45.0M | 3.17% | 3,948,653 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $43.3M | 3.06% | 3,298,289 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $33.6M | 2.37% | 1,911,433 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $32.7M | 2.31% | 750,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $32.5M | 2.29% | 5,000,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $29.8M | 2.10% | 1,988,084 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $29.7M | 2.09% | 3,100,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $18.8M | 1.33% | 800,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $17.5M | 1.23% | 7,692,300 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $16.6M | 1.17% | 2,311,164 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $15.9M | 1.12% | 1,419,714 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $13.1M | 0.92% | 500,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $12.6M | 0.89% | 290,000 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $10.5M | 0.74% | 5,397,488 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $8.0M | 0.56% | 750,000 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $7.7M | 0.54% | 1,500,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $7.3M | 0.52% | 453,686 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $6.4M | 0.45% | 427,866 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $3.1M | 0.22% | 1,575,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.4M | 0.17% | 483,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.